Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.
about
Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapyHydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib®), a phase III clinical stage anti-cancer agent.Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC/MS/MS.Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
P2860
Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.
@en
type
label
Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.
@en
prefLabel
Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.
@en
P2093
P356
P1433
P1476
Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.
@en
P2093
P2888
P304
P356
10.1038/SJ.ONC.1210350
P407
P577
2007-03-19T00:00:00Z
P5875
P6179
1024002673